Who is sponsoring NCT04555551?

NCT04555551 is sponsored by Memorial Sloan Kettering Cancer Center.

What condition does NCT04555551 study?

NCT04555551 studies Multiple Myeloma.

What drugs are being tested in NCT04555551?

Interventions: Infusion of MCARH109 T cells.

What is the status of NCT04555551?

NCT04555551 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-09-16 · How we verify

Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

NCT04555551 Phase 1 ACTIVE_NOT_RECRUITING

This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment. The study treatment could stop the growth of the cancer, but it could also cause side effects.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1
Status	ACTIVE_NOT_RECRUITING
Enrolment	17
Start date	2020-09-08
Completion	2026-08

Conditions

Multiple Myeloma

Interventions

Infusion of MCARH109 T cells

Primary outcomes

maximum tolerated dose (MTD) — 1 year
The MTD is defined as the highest dose with an observed incidence of DLT in no more than one out of six patients treated at a particular dose level. All patients treated in a dose cohort will be observed a minimum of 30 days before the T cell dose can be escalated.

Countries

United States